GlobeNewswire Inc.··NaMolecular Partners Advances Radio-DARPin Pipeline as Cash Runway Extends to Late 2027
Molecular Partners advances Radio-DARPin clinical programs with CHF 79M runway through late 2027, initiating trials for DLL3-targeted SCLC and cholangiocarcinoma treatments.
MOLNclinical trialimmunotherapy